3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Gliosarcoma
131
Glioblastoma
128
Central Nervous System Neoplasms
58
Glioma
51
Brain Neoplasms
48
Astrocytoma
45
Oligodendroglioma
32
Sarcoma
23
Sarcoma, Ewing
22
Rhabdomyosarcoma
18
Neuroblastoma
14
Medulloblastoma
14
Ependymoma
14
Osteosarcoma
10
Neoplasms
6
Choroid Plexus Neoplasms
6
Wilms Tumor
5
Recurrence
5
Ovarian Neoplasms
5
Neuroectodermal Tumors, Primitive, Peripheral
5
Glioma, Subependymal
5
Familial ependymoma
5
Rhabdoid Tumor
4
Pinealoma
4
Optic Nerve Glioma
4
Neuroectodermal Tumors, Primitive
4
Leiomyosarcoma
4
Diffuse Intrinsic Pontine Glioma
4
Testicular Neoplasms
3
Kidney Neoplasms
3
Interventions
repotrectinib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
capmatinib
1
Trabectedin
1
Temozolomide
1
Radiation
1
Oncolytic Virotherapy
1
Irinotecan
1
Interferon-gamma
1
Immunotherapy
1
FANG vaccine
1
Doxorubicin
1
Dexamethasone
1
Cyclophosphamide
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Temozolomide
×
Sarcoma
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts